Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.17 | 1.95 |
NAV | ₹15.90 | ₹412.09 |
Fund Started | 14 Sep 2023 | 04 Jun 1999 |
Fund Size | ₹1382.60 Cr | ₹3416.13 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 50.48% | 43.19% |
3 Year | - | 22.90% |
5 Year | - | 28.60% |
1 Year
3 Year
5 Year
Equity | 99.23% | 96.73% |
Cash | 0.77% | 3.27% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 14.02% |
Cipla Ltd. | 8.17% |
Divi's Laboratories Ltd. | 7.91% |
Lupin Ltd. | 6.25% |
Ipca Laboratories Ltd. | 4.08% |
Gland Pharma Ltd. | 4.00% |
Aurobindo Pharma Ltd. | 3.44% |
Piramal Pharma Ltd. | 3.41% |
Dr. Reddy's Laboratories Ltd. | 3.32% |
Eris Lifesciences Ltd. | 3.27% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.99% |
Max Healthcare Institute Ltd. | 6.26% |
Divi's Laboratories Ltd. | 6.21% |
Poly Medicure Ltd. | 5.38% |
Lupin Ltd. | 5.12% |
Lonza Group Ag | 4.55% |
Cipla Ltd. | 4.54% |
Krishna Institute of Medical Sciences Ltd | 3.99% |
Jupiter Life Line Hospitals Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.51% |
Name | Dhruv Muchhal | Tanmaya Desai |
Start Date | 14 Sep 2023 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 14 Sep 2023 | 04 Jun 1999 |
Description
Launch Date